

Reference number(s)
3000-A

SPECIALTY GUIDELINE MANAGEMENT

JETREA (ocriplasmin intravitreal injection)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Jetrea is indicated for the treatment of symptomatic vitreomacular adhesion.

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Vitromacular adhesion

Authorization of 90 days for a single dose (for each eye) may be granted for treatment of symptomatic vitromacular adhesion.

III. REFERENCES

1. Jetrea [package insert]. Iselin, NJ: Thrombogenics, Inc; May 2017.